Publications

The Add-Aspirin trial has had a number of publications. Please find below a list of each of these publications and a link to access the journal article.

  • 2023: Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial, British Journal of Cancer 

 

 

  • 2017: Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. Clinical Trials

 

  • 2017: Co-enrolment of Participants into Multiple Cancer Trials: Benefits and Challenges. Clinical Oncology

 

 

  • 2016: ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemporary Clinical Trials

 

  • 2014: Are the benefits of aspirin in colorectal cancer limited to PIK3CA mutated cancers? Annals of Oncology

 

  • 2011: Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? BR J Cancer

Contact Details

If you are an individual who is interested in taking part in Add-Aspirin, please talk to your doctor who will be able to consider whether you are suitable for the trial.

For healthcare professionals

Please log into the members area for Add-Aspirin contact details.

Register Interest

For healthcare professionals

If your centre would like to recruit participants to Add-Aspirin, contact us:
mrcctu.add-aspirin@ucl.ac.uk

Register a participant

From Monday 16th March 2020, to RANDOMISE a participant in the UK please call +44 (0)20 7670 4925, rather than the usual randomisation line.

To RANDOMISE a participant from Republic of Ireland or India only, please use the 'Register a participant' link above to randomise online. Please make sure to press 'Randomise' once logged in to the server.

Unblind a participant in the UK

Unblind a participant in the RoI

Unblind a participant in India